4-{[4-({4-[(E)-2-氰基乙烯基]-2,6-二甲基苯基}氨基)-2-嘧啶基]氨基}苯甲腈盐酸盐(1:1)置于potassium Carbonate体系中,用 水 作为反应溶剂,化学反应 3.0H,以18.6 G的收率获得产物利匹韦林 参考文献: Improved Process For Preparation Of Rilpivirine And Pharmaceutically Acceptable Salts Thereof[fr] Procédé Amélioré Pour La Préparation De Rilpivirine Et De Sels Pharmaceutiquement Acceptables De Celle-Ci 标题: Improved Process For Preparation Of Rilpivirine And Pharmaceutically Acceptable Salts Thereof[fr] Procédé Amélioré Pour La Préparation De Rilpivirine Et De Sels Pharmaceutiquement Acceptables De Celle-Ci 摘要:本发明公开了一种改进的利托那韦盐酸盐制备工艺.该工艺包括a) 在相转移催化剂的存在下,反应3-(4-氨基-3,5-二甲基苯基)-丙烯腈盐酸盐和4-[(4-氯嘧啶-2-基)氨基]苯腈,然后与酸盐化;b) 将利托那韦酸加盐转化为利托那韦盐酸盐.
专利号:US-2022233673-A1 优先权日:2019-06-04 标 题:METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF 发明人:BILLET ANNE; SCHMIDT FRÉDÉRIC; JOHANNES LUDGER; SERVENT DENIS; MOURIER GILLES; TARTOUR ÉRIC; KAY MICHAEL; FULCHER JAMES M 权利人:INST CURIE; CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES CEA; APHP ASSIST PUBLIQUE HOPITAUX DE PARIS; UNIV PARIS; UNIV OF UTAH RESEARCH FOUDATION; UNIV UTAH RES FOUND 摘要:A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.
专利号:US-2025179033-A1 优先权日:2021-12-30 标 题 :New antiviral triazole derivatives, their synthesis and their use for treatment of mammalian viral infections 发明人:MAKAROV VADIM; RIABOVA OLGA; LANE THOMAS R; EKINS SEAN 权利人:COLLABORATIONS PHARMACEUTICALS INC; FEDERAL RES CENTER FUNDAMENTALS OF BIOTECHNOLOGY RUSSIAN ACADEMY OF SCIENCE 摘要:A family of triazole derivatives is described. Also described is the use of these triazole derivatives in treating or preventing viral infections, such as human immunodeficiency virus (HIV) infections, and the diseases caused by these infections, such as acquired immunodeficiency syndrome (AIDS). The triazole derivatives, for example, comprise a central triazole group with two substituents comprising an aryl or heteroaryl group. Exemplary derivatives showed excellent HIV inhibitory activity against both wild-type and selected mutant strains of HIV.
专利号:WO-2025124470-A1 优先权日:2023-12-15 标 题:Doravirine intermediate, and use thereof and synthesis method therefor 发明人:GAO ZHANGBIN; WEN SHAOPENG; YANG JINHONG; JU JINGJING; MAO WENXIU 权利人:SHANDONG CHENGCHUANG BLUE SEA PHARMACEUTICAL TECH CO LTD 摘要:The present invention relates to a doravirine intermediate, and the use thereof and a synthesis method therefor, which belong to the technical field of pharmaceutical chemistry. The method for synthesizing the doravirine intermediate comprises the following steps: (1) mixing ethyl 2-fluoroacetate with 4-ethoxy-1,1,1-trifluoro-3-buten-2-one with solvent I, and then dropwise adding sodium bis(trimethylsilyl)amide to form compound 1; (2) adding an ammonia source into the reaction liquid of compound 1 to obtain compound 2; (3) dissolving compound 2 in solvent II, adding a catalyst, and heating and ring-closing the mixture to obtain compound 3; and (4) dissolving compound 3 in toluene, adding thionyl chloride, and dropwise adding pyridine to obtain 2-hydroxy-3-fluoro-4-trifluoromethylpyridine. The synthesis method of the present invention has a low raw material cost and a short process period, is environmentally friendly, and is suitable for process scaled-up production.
专利号:US-5935946-A 优先权日:1997-07-25 标 题 :Nucleotide analog composition and synthesis method 发明人:MUNGER JR JOHN D; ROHLOFF JOHN C; SCHULTZE LISA M 权利人:GILEAD SCIENCES INC 摘要:The invention provides a composition comprising bis(POC)PMPA and fumaric acid (1:1). The composition is useful as an intermediate for the preparation of antiviral compounds, or is useful for administration to patients for antiviral therapy or prophylaxis. The composition is particularly useful when administered orally. The invention also provides methods to make PMPA and intermediates in PMPA synthesis. Embodiments include lithium t-butoxide, 9-(2-hydroxypropyl) adenine and diethyl p-toluenesulfonylmethoxyphosphonate in an organic solvent such as DMF. The reaction results in diethyl PMPA preparations containing an improved by-product profile compared to diethyl PMPA made by prior methods.
专利号:CN-118510750-A 优先权日:2022-01-05 标 题 :Improved synthesis of rilpivirine glycine particles
专利号:CN-113388600-B 优先权日:2021-06-16 标题:A kind of aldoxime dehydratase and its application in catalytic synthesis of aromatic nitrile compounds
1: Serris A, Ferre VM, Le Hingrat Q, Bachelard A, Charpentier C, Exarchopoulos M, Damond F, Phung BC, Landman R, Yazdanpanah Y, Descamps D, Joly V, Peytavin G, Ghosn J. Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results. J Antimicrob Chemother. 2024 Sep 17:dkae308. doi: 10.1093/jac/dkae308. Epub ahead of print. 11(9):ofae480. doi: 10.1093/ofid/ofae480. 3: Konishi K, Onozuka D, Okubo M, Kasamatsu Y, Kutsuna S, Shirano M. Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world setting. BMC Infect Dis. 2024 Sep 16;24(1):979. doi: 10.1186/s12879-024-09904-x.
合成参考文献
参考文献:10.1016/s0140-6736(11)61106-9 摘要:HIV/AIDS and the road to Rome. Lancet. 2011 Jul 16;378(9787):199. doi: 10.1016/s0140-6736(11)61106-9. 参考文献:10.1016/s0140-6736(11)60992-6 摘要:Schrijvers R, Desimmie BA, Debyser Z. Rilpivirine: a step forward in tailored HIV treatment. Lancet. 2011 Jul 16;378(9787):201–3. doi: 10.1016/s0140-6736(11)60992-6. 参考文献:10.1016/s0140-6736(11)60983-5 摘要:Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K; THRIVE study group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011 Jul 16;378(9787):229–37. doi: 10.1016/s0140-6736(11)60983-5. 参考文献:10.1016/s0140-6736(11)60936-7 摘要:Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K; ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011 Jul 16;378(9787):238–46. doi: 10.1016/s0140-6736(11)60936-7.